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Background Many potential environmental risk and protective factors, and peripheral biomarkers for 
ADHD have been investigated, but their consistency and magnitude are unclear. We aimed to 
systematically appraise the published evidence of association between potential risk factors, protective 
factors, or peripheral biomarkers, and ADHD.  
Methods We did an umbrella review of meta-analyses. We searched PubMed, Embase, and the 
Cochrane Database of Systematic Reviews from inception to Oct 31, 2019, and screened the references 
of relevant articles. We included systematic reviews providing meta-analyses of observational studies 
that examined associations of potential environmental risk factors, protective factors, or peripheral 
biomarkers with diagnosis of ADHD. We included meta- analyses using categorical ADHD diagnosis 
criteria according to DSM, or hyperkinetic disorder according to ICD, and accepted less rigorous criteria 
such as self-reports. We excluded articles that did not examine environmental risk factors, protective 
factors, or peripheral biomarkers of ADHD; articles that did not include a meta-analysis; and articles 
that did not present enough data for re-analysis. We excluded non-human studies, primary studies, 
genetic studies, and conference abstracts. We calculated the summary effect estimates (odds ratio [OR], 
relative risk [RR], and weighted mean difference [WMD]), 95% CI, heterogeneity I2 statistic, 95% 
prediction interval, small study effects, and excess significance biases. We did analyses under credibility 
ceilings, and assessed the quality of the meta- analyses with AMSTAR 2 (A Measurement Tool to Assess 
Systematic Reviews 2). This study is registered with PROSPERO, number CRD42019145032.  
Findings We identified 1839 articles, of which 35 were eligible for inclusion. These 35 articles yielded 
63 meta-analyses encompassing 40 environmental risk factors and protective factors (median cases 16 
850, median population 91 954) and 23 peripheral biomarkers (median cases 175, median control 187). 
Evidence of association was convincing (class I) for maternal pre-pregnancy obesity (OR 1·63, 95% CI 
1·49–1·77), childhood eczema (1·31, 1·20–1·44), hypertensive disorders during pregnancy (1·29, 
1·22–1·36), preeclampsia (1·28, 1·21–1·35), and maternal acetaminophen exposure during pregnancy 
(RR 1·25, 95% CI 1·17–1·34). Evidence of association was highly suggestive (class II) for maternal 
smoking during pregnancy (OR 1·6, 95% CI 1·45–1·76), childhood asthma (1·51, 1·4–1·63), maternal 
pre- pregnancy overweight (1·28, 1·21–1·35), and serum vitamin D (WMD −6·93, 95% CI −9·34 to 
−4·51). 
Interpretation Maternal obesity, overweight, preeclampsia, and hypertension; maternal acetaminophen 
exposure or smoking during pregnancy; and childhood atopic diseases were strongly associated with 
ADHD in offspring. Previous familial studies suggest that pre-pregnancy obesity, overweight, and 
maternal smoking during pregnancy are confounded by familial or genetic factors, and further high-








ADHD is one of the most common childhood neuro-developmental disorders, characterised by 
inattention, hyperactivity, and impulsive behavior.1 The prevalence of ADHD, which was estimated  
to be 5–7%,2,3 is expected to increase4 as the classification of ADHD is advanced from DSMIV to 
DSM5. Years lived with disability per 100000 children younger than 5 years was  
2.0 in 2016.5 
Numerous studies have been done to better understand and advance the diagnosis, prognosis, and 
treatment of the disorder across neurodevelopmental stages, with an emerging core focusing on early 
detection and prevention.5 The complex nature of ADHD pathophysiology has been reflected by 
multimodal research studies investigating both the association of a multitude of genetic and non-genetic 
(i.e. environmental) risk/protective factors with ADHD,6,7 and potential biomarkers which may reflect 
the effect of these factors on the disorder.7 While substantial advances have been made in understanding 
the genetic factors linked to ADHD,6,8 findings on environmental factors and peripheral biomarkers 
have been inconsistent with unclear magnitude of association with ADHD.7,9 Numerous meta-analyses 
and systematic reviews for environmental risk/protective factors and biomarkers have been published. 
However, these are usually restricted to a single topic and some of their results may be affected by 
several types of bias including excess significance bias and publication bias.10 Furthermore, they did 
not apply hierarchy of evidence among the various environmental factors and peripheral biomarkers to 
stratify their level of association with ADHD. Finally, with the lack of an established pathophysiology 
of the disorder, the boundaries between risk/protective factors and biomarkers may become blurred, and 
pragmatic evidence synthesis encompassing both domains are preferred.11 
The current umbrella review —a systematic collection and evaluation of multiple systematic reviews 
and meta-analyses performed on a specific research topic12 —identifies and appraises for the first time 
the consistency and magnitude of evidence of environmental factors and peripheral biomarkers 




We followed state-of-the-art methods of umbrella reviews.11,13,14 The study was registered in 
PROSPERO (registration: CRD42019145032). We followed the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) reporting guideline (Appendix pp 2–3).15 The 
screening, data extraction and methodological appraisal of included studies were conducted by at least 
two independent investigators (JHK and JYK). 
Literature search strategy and eligibility criteria 
We systematically searched PubMed/MEDLINE, Embase, and the Cochrane Database of Systematic 
Reviews from inception to October 31st, 2019 to identify eligible articles, employing search keywords 
such as attention-deficit/hyperactivity disorder and meta-analysis (Appendix p 4). For identifying 
eligible articles, two investigators (JHK and JYK) independently screened titles, abstracts, and full texts 
(Figure 1). We also manually searched the references of relevant studies to identify further eligible 
articles. Any disagreement was solved by consultation between three authors (JYK, JHK, and JIS). 
We only included systematic reviews providing meta-analyses of observational studies (e.g. cohort, 
case-control, and cross-sectional studies) examining associations of potential environmental 
risk/protective factors or peripheral biomarkers with diagnosis of ADHD. There was no language 
restriction. The definitions of risk/protective factor and biomarker followed those of the World Health 
Organization (Appendix p 5). We included meta-analyses using categorical ADHD diagnosis criteria 
according to DSM or hyperkinetic disorder according to ICD and accepted less rigorous criteria such 
as self-reports as well.  
We excluded articles not examining environmental risk/protective factors or peripheral biomarkers of 
ADHD, not performing a meta-analysis, and not presenting sufficient data for re-analysis (i.e. individual 
study estimates or necessary data to calculate these). We excluded non-human studies, primary studies, 
genetic studies, and conference abstracts. When two or more meta-analyses studied an identical topic, 
we selected only one meta-analysis to avoid overlaps, employing the following procedure. First, we 
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prioritized the meta-analysis with adjusted study estimates over those with crude estimates. Next, we 
scored the meta-analyses by their recency and quality, utilizing items from AMSTAR 2 (A Measurement 
Tool to Assess Systematic Reviews 2), a critical meta-analysis appraisal tool16 and chose the one with 
the highest score (Appendix p 6). Finally, when two or more meta-analyses had the same score, we 
chose the one with the largest number of studies. For meta-analyses of risk/protective factors, some 
meta-analyses studied “later” risk/protective factors possibly measured after childhood and thus 
temporal causality with ADHD-onset is unclear (e.g. obesity, eczema, and asthma). In these instances, 
we included articles providing meta-analysis of childhood-only population or created new subsets by 
including individual studies only of which the mean age was 18 or below. We did not consider such 
temporal relationships in meta-analyses of biomarkers, as most biomarker studies used samples derived 
from those already diagnosed with ADHD. We excluded meta-analyses studying indices of cognitive 
function (e.g. verbal fluency, risky decision making, and emotion dysregulation), as these have recently 
been described in another umbrella review.17 We also excluded meta-analyses regarding behavioral 
outcomes of ADHD (oral health, suicidal attempts, dietary pattern, internet addiction, and unintentional 
physical injuries). The list of the meta-analyses excluded in the text-screening stage is provided in 
Appendix pp 7–9. 
Data extraction 
For each eligible article, two investigators (JHK and JYK) independently extracted the name of the first 
author, publication year, environmental risk/protective factor or peripheral biomarker of interest, the 
number of ADHD cases and study population, the maximally adjusted individual study estimate and 
corresponding 95% confidence interval (CI), and metrics used in the original analyses such as odds 
ratio (OR), relative risk (RR), hazard ratio (HR), weighted mean difference (WMD), Cohen’s d, and 
Hedges’ g. We also extracted the individual study designs of meta-analyses (e.g. cohort, case-control). 
Data analysis 
We adopted a series of statistical tests to assess the robustness and consistency of the identified 
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association. While environmental risk/protective factors and peripheral biomarkers might be of different 
use in clinical situations, we used identical assessment method to test the robustness of the association 
itself regardless of causality or temporal relationships with ADHD, as in previous umbrella reviews.11,13 
We re-analyzed each eligible meta-analysis using the extracted individual study estimates. Metrics 
followed those of the original meta-analyses. Moreover, we calculated the summary effect estimate and 
p-values of eligible meta-analyses under both fixed and random effects models. Statistical significance 
was claimed at p-value < 0‧05. Further, we also assessed p-values below 10−3 or 10−6 thresholds18,19 and 
performed Cochran’s Q test and calculated the I2 statistic for the evaluation of heterogeneity between 
studies (I2 > 50% is considered to indicate high heterogeneity).20 We estimated the 95% prediction 
interval, the range we expect the effect of the association will lie for 95% of future studies.21 We assessed 
the presence of small study effects (i.e. large studies have significantly more conservative results than 
smaller studies) with the regression asymmetry test proposed by Egger and colleagues.22 Small study 
effect was claimed when Egger p-value < 0‧1 with the effect of the largest study being more 
conservative than random effects estimate. For statistically significant meta-analyses, we assessed the 
presence of potential excess significance bias, a measure of literature bias that compares the expected 
versus the observed number of statistically significant (p-value < 0‧05) individual studies.23 Random-
effects meta-analyses were performed after applying various levels (5/10/15/20%) of credibility ceilings 
to account for potential methodological limitations of observational studies which might result in 
spurious significant results.24,25 All statistical tests were two-tailed. The software used for the analysis 
was R version 3.5.1. and its packages.26,27 For each eligible article, two investigators (JHK and JYK) 
independently assessed the methodological quality of the meta-analyses using AMSTAR 2 and reached 
consensus through discussion in case of disagreement.16 
Determining the credibility of evidence 
In accordance with the previous umbrella reviews,11,13,14,28 we classified the eligible meta-analyses 
according to the strength of the evidence of potential environmental risk/protective factors and 
peripheral biomarkers for ADHD into five levels: convincing (class Ⅰ), highly suggestive (class Ⅱ), 
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suggestive (class Ⅲ), weak (class Ⅳ), and not significant (NS) (Figure 2). Criteria for the level of 
evidence were based on p-values a under random effects model, the number of ADHD cases, the 
statistical significance of the largest study, the I² statistic, small study effects, excess significance bias, 
random effects summary estimate under a 10% credibility ceiling, and the 95% prediction interval. For 
associations graded as convincing or highly suggestive evidence, we attempted further assessment for 
the robustness of the evidence by performing subset analyses of cohort studies (retrospective and 
prospective), prospective cohort studies, and study estimates adjusted for at least one covariate. 
Role of the funding source 
There was no funding source for this study. All authors had full access to all of the study data and the 




From the three databases, we initially identified 1 839 articles, 35 of which were finally eligible (Figure 
1).29-63 The 35 eligible articles provided 63 unique meta-analyses (40 potential environmental 
risk/protective factors and 23 peripheral biomarkers) (Table 1, 2, Appendix pp 10–12, 17–34). The 40 
meta-analyses of environmental risk/protective factors were based on data of 649 669 total ADHD cases, 
32 342 401 total population, the median number of 16 850 ADHD cases per meta-analysis (inter-quartile 
range [IQR] 1 490 to 37 086, range 79 to 92 426), and the median number of 83 884 total population 
per meta-analysis (IQR 14 095 to 1 276 239, range 1 072 to 9 244 291). Twenty-nine meta-analyses 
were based on cohort studies, 15 of which also included case-control or cross-sectional studies. The 
median number of study estimates of the meta-analyses was 6 (IQR=4 to 8, range 2 to 30). Effect metrics 
used were either RR, OR, or HR. A total of 31 (78%) associations were statistically significant under 
random effects model, of which 23 (58%) had a p-value < 10-3, and 12 (30%) a p-value < 10-6. Out of 
31 statistically significant associations, 25 had more than 1 000 ADHD cases. Nineteen (48%) 
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associations showed large heterogeneity (I2 > 50%). Fifteen (38%) statistically significant associations 
had neither small study effects nor excess significance bias. The 95% prediction interval excluded the 
null in only 14 (35%) associations, and 19 (48%) associations retained statistical significance under a 
10% credibility ceiling.  
The 23 meta-analyses of peripheral biomarkers were based on data of 13 807 total ADHD cases and 23 
649 total controls, the median number of 175 ADHD cases per meta-analysis (IQR 136 to 798, range 
53 to 2 557), and the median number of 187 control per meta-analysis (IQR 91 to 921, range 39 to 8 
154). Meta-analyses were only based on a case-control or cross-sectional design. The median number 
of study estimates of the meta-analyses was 7 (IQR 5 to 9, range 3 to 19). Used effect metrics were 
either WMD, Cohen’s d, or Hedges’ g. A total of 14 (61%) associations were statistically significant 
under random effects model, 6 (26%) of which had p-value < 10−3, and only 2 (9%) p-value < 10−6. Out 
of 14 statistically significant associations, 5 had more than 1 000 ADHD cases. Fifteen associations 
(65%) showed large heterogeneity (I2 > 50%). Eleven (48%) statistically significant associations had 
neither small study effects nor excess significance bias. The 95% percent prediction interval excluded 
the null in only two (9%) associations, and 8 (35%) associations retained statistical significance under 
10% credibility ceiling. 
Quality assessment 
AMSTAR 2 quality assessment was available for all but one (maternal cell phone use). For 25 meta-
analyses articles of environmental risk/protective factors, 13 were graded as high quality, one moderate, 
and 11 low or critically low, mainly because the article did not report the protocol for the systematic 
review (Table 1). When the quality assessment criterion for the protocol was ruled out, only three were 
graded as low or critically low. Out of nine meta-analysis articles of peripheral biomarkers, two were 
graded as high quality, and the rest as low or critically low (Table 2). When we ruled out the protocol 




Hierarchical level of evidence: potential environmental risk/protective factors 
A total of five environmental risk factors were graded as convincing evidence (class I) (Table 1, Figure 
3) —pre-pregnancy obesity (defined as body mass index [BMI] of 30 kg/m2 or higher)59 (OR=1·63, 95% 
CI 1·49–1·77), childhood eczema (OR=1·31, 1·2–1·44), hypertensive disorders during pregnancy 
(including chronic hypertension, gestational hypertension, and preeclampsia)50 (OR=1·29, 1·22–1·36), 
preeclampsia (de novo or superimposed on chronic hypertension)50 (OR=1·28, 1·21–1·35), and 
maternal acetaminophen exposure during pregnancy (RR=1·25, 1·17–1·34) —and three were graded 
as highly suggestive evidence (class Ⅱ) (Table 1, Figure 3) —maternal smoking during pregnancy 
(OR=1·6, 1·45–1·76), childhood asthma (OR=1·51, 1·4–1·63), and pre-pregnancy overweight (defined 
as BMI between 25 and 29·9 kg/m2)59 (OR=1·28, 1·21–1·35). Among eight environmental risk factors 
with high level of evidence (class Ⅰ or Ⅱ), four were maternal metabolic syndrome (pre-pregnancy 
obesity, overweight, preeclampsia, and hypertensive disorders during pregnancy) and two were 
childhood atopic diseases (childhood eczema and asthma). 
Some markers of perinatal hypoxic conditions (5-min Apgar score < 7 and breech/transverse 
presentation) and preterm birth were graded as suggestive evidence (class ⅠⅠⅠ). Factors related to 
the parenting environment were at best graded as class IV evidence (parental education level and singly 
parent family). Meanwhile, only one factor, breastfeeding, showed statistically significant protective 
effects against ADHD (class IV). Only four associations had effect sizes larger than 2 (eating disorder, 
preterm birth/low birth weight, low education level of father, and head trauma), which were all class Ⅳ 
evidence. 
Meta-analyses included studies ascertaining ADHD with parental or physician report, medical records 
of diagnosis or ADHD medication, or self-report, and only four class IV meta-analyses included studies 
using self-report (childhood/adolescent obesity, head trauma, preterm or low birth weight, and maternal 
gestational diabetes).31,34,45,57 The subset analyses excluding the self-report studies are provided in 
Appendix p 13. 
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Hierarchical level of evidence: potential peripheral biomarkers 
Only one biomarker was graded as high level of evidence, which was serum vitamin D level in ADHD 
patients (WMD=−6·93, −9·34–−4·51, class II) (Table 2, Figure 3). Two were graded as suggestive 
evidence (higher blood lead and lower blood magnesium in ADHD, class III). 
Sensitivity subset analyses 
Subset analyses for class I and II were available for the eight meta-analyses of environmental risk 
factors (Appendix p 14). In the cohort subset analyses, four maternal factors (pre-pregnancy obesity, 
overweight, maternal acetaminophen exposure during pregnancy, and maternal smoking during 
pregnancy) retained their level of evidence, while the rest were downgraded to class III or IV or the 
subset analysis was not available since there were less than two cohort studies. The same four maternal 
factors were also graded as class I or II in the prospective cohort subset analyses. In the subset analyses 
of study estimates adjusted for at least one covariate, all eight retained their level of evidence.  
 
Discussion 
This study is the first umbrella review to systematically and quantitatively collect and assess the 
hierarchy of evidence for potential environmental risk/protective factors and peripheral biomarkers of 
ADHD. Only nine associations showed evidence of high credibility: Maternal acetaminophen exposure 
during pregnancy, childhood eczema, hypertensive disorder during pregnancy, preeclampsia, and 
maternal pre-pregnancy obesity were graded as convincing evidence (class I), and maternal smoking 
during pregnancy, childhood asthma, maternal pre-pregnancy overweight, and serum vitamin D level 
were graded as highly suggestive evidence (class II). 
There was convincing evidence that maternal acetaminophen exposure during pregnancy was 
associated with a higher risk of ADHD in offspring, retaining the level of evidence in all three subset 
analyses. Various potential mechanisms have been suggested such as excess toxic N-acetyl-p-
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benzoquinoneimine formation, oxidative stress due to inflammation-induced immune activation, brain-
derived neurotropic factor alteration, endocannabinoid dysfunction, Cox-2 inhibition, and endocrine 
disruption.56,64 Although the exact biological mechanism has not yet been identified, one hypothesis is 
that prenatal acetaminophen exposure affects normal neurodevelopment and it is consistent with the 
evidence that 1) acetaminophen readily crosses the placenta65 and blood-brain barrier66 and 2) prenatal 
acetaminophen exposure during the third trimester of pregnancy, the period the fetal brain grows rapidly 
and is thereby highly sensitive to stimulation,67 is associated with a higher risk of ADHD than in earlier 
trimesters.56,68,69 The association is supported by a sibling-controlled study which reports that children 
exposed to prenatal acetaminophen for more than 28 days had substantially poorer neurodevelopment 
than those exposed less than 28 days.67 Moreover, one prospective cohort study reported positive dose-
responsive associations with offspring ADHD diagnosis for maternal acetaminophen biomarkers.70 
However, this association must be interpreted in light of possible confounding by indication since the 
same result can postulate that use of the medication may imply presence of maternal comorbidities 
(such as inflammation and infections), which may themselves increase the risk of ADHD in 
offspring.56,71 Meanwhile, some studies reported the retained association with statistical significance 
even after adjusting for indications of acetaminophen.56,68,69 In interpreting the current acetaminophen 
results, prudent caution is required as our evidence grading did not consider the biological plausibility 
of the association, nor considered all the potential confounders; the association itself does not 
necessarily indicate causality. 
Components of maternal metabolic syndrome were associated with an increased risk of ADHD in 
offspring with convincing evidence for pre-pregnancy obesity, preeclampsia, and hypertensive 
disorders during pregnancy, and highly suggestive for pre-pregnancy overweight, two of which survived 
all three subset analyses. One possible underlying mechanism involves a changed in utero environment 
created by metabolic syndrome. Potential causative bases include reduced placental blood flow, 
maternal oxidative stress, and maternal inflammatory pathways.72 As inflammatory agents induce the 
increased permeability of the blood-brain barrier of the immature fetus, they can reach the fetal brain,73 
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possibly involving in neuroanatomical alteration.72,74 Altered fetal developmental trajectories, 
especially in the brain, may increase the risk of long-term vascular, cognitive and psychiatric sequelae 
in the offspring,75-77 which may subsequently lead to higher risk of ADHD as well as other 
neurodevelopmental disorders including autism spectrum disorder.78 The causal relationship between 
preeclampsia and offspring ADHD is further supported by a sibling-matched study reporting similar 
effect sizes between sibling-matched and unmatched population model (sibling-matched: HR 1·13, 
1·05–1·22; unmatched population: HR 1·15, 1·12–1·19),79 which implies that the association is 
possibly independent of genetic or familial confounding. On the other hand, the association of pre-
pregnancy obesity or overweight with ADHD seems to be confounded by genetic or familial factors, as 
studies have reported attenuated, non-significant associations in sibling-matched models (obesity: HR 
1·15, 0·85–1·56; overweight: HR 0·98, 0·83–1·16; pre-pregnancy BMI: regression coefficient −0·08, 
−0·23–0·06).80,81 
In accordance with the evidence that ADHD is one of the common co-occurring conditions in autism 
spectrum disorder,82 it is notable that some components of metabolic syndrome (preeclampsia, 
hypertensive disorders during pregnancy, and maternal pre-pregnancy overweight) and acetaminophen 
exposure during pregnancy had robust associations with both autism spectrum disorder with a high level 
of evidence (Appendix p 15).11 This findings may support the pathological similarity between the two 
psychiatric disorders, previously characterized by reports of similarity of brain structural alterations in 
ADHD and autism,74 and shared genetic influences, which suggest similar biological pathways.83 One 
possible hypothesis is that shared environmental risk factors of ADHD and autism spectrum disorder 
may have a transdiagnostic feature.84,85 Further studies regarding the possible linkage between the 
disorders with the consideration of abovementioned findings would be worthwhile. 
Childhood atopic diseases were associated with an increased risk of ADHD with convincing evidence 
for childhood eczema and highly suggestive evidence for childhood asthma. Neuroimmunological 
pathways and psychological mechanisms have been broadly accepted in terms of etiology,38,51 which 
respectively account for the disruptive effect of allergic inflammatory cytokines86 and elevated 
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psychological stress levels,87 damaging ADHD-relevant brain circuits during early-life on which the 
brain is particularly sensitive to stimulation.88 However, the causality of the comorbidity of atopic 
diseases and ADHD is still a matter of debate. Indeed, previous studies suggested that early ADHD is a 
predictor of subsequent asthma.51,88 Some twin studies have been conducted to control for genetic or 
familial factors one of which suggested genetic influences underlying the association between asthma 
and subsequent ADHD symptoms by reporting a significant correlation between them (correlation 
coefficient 0·23, 0·04–0·37).89 However, another study reported conflicting findings that cross-twin 
cross-trait correlation between ADHD and asthma is higher between dizygotic twins than monozygotic 
twins (correlation coefficient: monozygotic 0·05, −0·08–0·17; dizygotic same sex 0·13, 0·03–0·23), 
contradicting the notion of a shared genetic component in asthma and ADHD,90 and this result was also 
supported by other familial studies.91,92 Our findings should also be addressed in light of the large 
between-study heterogeneity in the asthma meta-analysis. The large heterogeneity may be attributed to 
heterogeneous nature of asthma such as diverse clinical presentation, multiple causes, and variable 
developmental courses93,94 and the fact that most individual studies were case-control or cross-sectional. 
Meanwhile, one suggested confounder of the association between eczema and subsequent ADHD 
symptoms is sleeping problems caused by eczema. Eczema was reported to be positively associated 
with impaired sleep quality,95 and childhood sleep problems were found to be associated with 
subsequent hyperactivity in a twin-matched study.96 
Maternal smoking during pregnancy showed highly suggestive evidence for the increased risk of ADHD, 
retaining the level of evidence in all three subset analyses. Potential mechanisms have been suggested 
proposing the harmful effect of cigarettes on child neurodevelopment.46 Meanwhile, three separate 
sibling studies97-99 controlled for familial or genetic confounding consistently reported non-significant, 
attenuated effect estimates, and a meta-analysis of these three studies reported an effect close to the null 
(OR 1·04, 0·95–1·15).46 Another sibling study reported effect estimates gradually being attenuated 
towards the null when adjusting for unmeasured confounders (unmatched population: HR 1·62, 1·56–
1·69; cousin comparison: HR 1·45, 1·24–1·68; sibling comparison: HR 0·88, 0·73–1·06).100 These 
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findings suggest that the association is confounded by familial or genetic factors, which supports the 
hypothesis that shared genetic components between mother and child are causes of ADHD rather than 
adverse effect of cigarettes.101,102 Maternal psychiatric conditions including ADHD may be another 
possible confounding factor in that they were associated with both smoking during pregnancy103 and 
offspring ADHD.  
We identified 23 potential peripheral biomarkers for ADHD. The evidence of association between 
ADHD and serum vitamin D was highly suggestive with large heterogeneity and 95% prediction 
interval including the null value. However, most peripheral biomarkers identified in our study were 
graded as low level partly owing to the low number of ADHD cases, probably attributable to the 
dearth of research in this field. Quality of meta-analyses were poorer than that of environmental factors, 
as many were lacking in protocol registration and risk of bias assessment. These findings are consistent 
with current consensus that biomarkers are not yet reliable enough to be used clinically. Consensus 
studies published in 2012 concluded that no single biomarker reliably predicts ADHD,104 while 
concurrent guidelines do not mention or recommend the use of any for the management of ADHD 
(Appendix p 16).105,106  
The current study has some limitations. First, due to the nature of observational studies, the identified 
associations do not necessarily imply causality. While we identified robust associations consistently 
found across the multiple studies, the possibility of confounding such as genetic linkage cannot be ruled 
out. The associations of maternal smoking, obesity, and overweight supported by high level of evidence 
were not replicated in familial studies, suggesting significant familial or genetic confounding 
underlying the association. Second, we could not consider changes in classification for ADHD and its 
varieties and could not distinguish between specific ADHD symptoms (i.e. inattention, hyperactivity, 
or co-occurrence of them) for diagnosing ADHD. Third, we could not assess potential environmental 
risk/protective factors or biomarkers of ADHD according to important factors such as sex, intellectual 
disability, and comorbid psychiatric disorders. Fourth, we assessed peripheral biomarkers but did not 
assess neurocognitive markers, which may act as biomarkers for ADHD.17 Fifth, there is no assumption 
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that the identified factors are independent. Furthermore, we could only address associations in the 
published meta-analyses and therefor might have missed those that had not been evaluated in preceding 
meta-analyses or underestimated some genuine environmental factors or biomarkers owing to the nature 
of the systematic review. For example, other reviews have argued that preterm birth is strongly 
associated with a higher risk of ADHD compared to other potential risk factors45,107 since the association 
was supported by sibling studies108 and dose-response relationship.109 However, in our review, preterm 
birth42 was graded as suggestive evidence (class Ⅲ), not meeting the criteria for highly suggestive (class 
Ⅱ) because random effects p-value was larger than 10−6 and the largest study was not statistically 
significant. This is partly because we did not reward high-quality study designs, such as familial studies 
or dose-response relationships, or further attempt to control for confounders in our evidence grading, 
which is another limitation of our review.  
Acknowledging these limitations, this umbrella review mapped and established the hierarchy of 
evidence among 63 potential environmental risk/protective factors and peripheral biomarkers of ADHD. 
Among them, only pre-pregnancy obesity, overweight, maternal acetaminophen exposure during 
pregnancy and maternal smoking during pregnancy retained high level of evidence in all subset analyses. 
These associations, however, are not necessarily causative and therefor further high-quality primary 
studies to confirm these findings would be valuable. 
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Panel: Environmental risk/protective factors and peripheral biomarkers for attention-
deficit/hyperactivity disorder: an umbrella review of the evidence 
 
<Evidence before this study> 
We searched PubMed/MEDLINE, Embase, and Cochrane Database of Systematic Reviews from 
inception to Oct 31st, 2019, for meta-analyses of observational studies regarding any environmental 
risk/protective factors and peripheral biomarkers of attention deficit/hyperactivity disorder, employing 
search terms such as attention-deficit/hyperactivity disorder and meta-analysis without any language 
restrictions. Our research identified numerous potential environmental risk/protective factors and 
peripheral biomarkers associated with attention deficit/hyperactivity disorder in systematic reviews 
and meta-analyses. However, some results have been inconsistent across studies, and it is unclear 
whether the claimed associations are prone to biases in literature such as excess significance bias and 
publication bias.  
 
<Added value of this study> 
To overcome the limitations of previous studies, we performed an umbrella review of meta-analyses. 
We conducted various bias assessment tests and applied criteria for determining the level of credibility 
of the associations. We identified and analyzed 63 unique associations of potential environmental 
risk/protective factors or peripheral biomarkers of attention deficit/hyperactivity disorder. Among these, 
eight environmental risk factors and one peripheral biomarker were identified as factors which were 
associated with the risk of attention deficit/hyperactivity disorder with high level of evidence (class I or 
II). Maternal pre-pregnancy obesity, childhood eczema, hypertensive disorders during pregnancy, 
preeclampsia, and maternal acetaminophen exposure during pregnancy were graded as convincing 
evidence (class I) and maternal smoking during pregnancy, childhood asthma, and maternal pre-
pregnancy overweight as highly suggestive evidence (class II). Considering peripheral biomarkers, 
evidence was scarce with few ADHD cases and p-values close to the significance threshold, and only 
serum vitamin D level was graded as highly suggestive evidence (class II). In subset analyses of 
prospective cohort studies, only maternal smoking during pregnancy, maternal acetaminophen exposure 
during pregnancy, and maternal pre-pregnancy obesity and overweight retained their level of evidence. 
 
<Implications of all the available evidence>  
We identified factors strongly associated with ADHD, which will help clinicians to identify children 
with high risks of ADHD and possibly lead to earlier diagnosis and treatment. We found that maternal 
metabolic syndromes, acetaminophen exposure during pregnancy, and childhood atopic diseases were 
strongly associated with ADHD, suggesting that immunologic pathways may play an important role in 
ADHD. Maternal metabolic syndromes and acetaminophen use during pregnancy were found to be 
robust environmental risk factors for both ADHD and autism spectrum disorder, suggesting their 
potential role as transdiagnostic risk factors. It should be noted that the identified associations are not 
necessarily causative, and high-quality studies are required to confirm their causality and assess the 




Table 1. Potential environmental risk/protective factors of ADHD 
Potential environmental 
risk/protective factor 
Author, year Number 























Large heterogeneity, small 
study effect, excess 
significance bias, or loss of 
significance under 10% 
credibility ceiling 
AMSTAR 2 quality 





Convincing (class I) 




11 Cohort OR 1·63 (1·49 to 1·77) 1·6E-29 30% 1·35 to 1·95 0·92 None Critically Low / Low 






OR 1·31 (1·2 to 1·44) 1·5E-08 0% 1·15 to 1·5 0·94 None Low / High 
Hypertensive disorders during 
pregnancy 






OR 1·29 (1·22 to 1·36) 1·2E-19 0% 1·2 to 1·38 0·73 None High / High 






OR 1·28 (1·21 to 1·35) 7·2E-19 0% 1·19 to 1·39 0·76 None High / High 
Maternal acetaminophen exposure 
during pregnancy 
Gou, et al. 2019 >1000 / 
244940 
8 Cohort RR 1·25 (1·17 to 1·34) 9·3E-11 26% 1·08 to 1·44 0·42 None Low / High 
Highly suggestive (class II) 






OR 1·6 (1·45 to 1·76) 3·8E-21 79% 1·15 to 2·22 0·004 Large heterogeneity * High / High 




11 Cross-sectional OR 1·51 (1·4 to 1·63) 1·9E-26 52% 1·26 to 1·82 0·05 Large heterogeneity; small 
study effect 
High / High 
26 
 




9 Cohort OR 1·28 (1·21 to 1·35) 1·4E-16 20% 1·14 to 1·43 0·068 Small study effect Critically Low / Low 
Suggestive (class III) 




11 NR OR 1·84 (1·36 to 2·49) 0·000077 48% 0·86 to 3·95 0·0003
7 
Small study effect * High / High 






OR 1·72 (1·27 to 2·34) 0·00047 85% 0·71 to 4·21 3·2e-
05 
Large heterogeneity; small 
study effect; loss of 
significance under 10% 
credibility ceiling * 
High / High 
Maternal SSRI exposure during pre-
pregnancy period 
Jiang, et al. 2018 39097 / 
1836001 
3 Cohort RR 1·59 (1·23 to 2·06) 0·00044 45% 0·12 to 
20·62 
0·76 Loss of significance under 
10% credibility ceiling * 
Low / High 
Maternal non-SSRI exposure during 
pregnancy 
Jiang, et al. 2018 23064 / 
1212802 
6 Cohort RR 1·5 (1·24 to 1·82) 0·000042 0% 1·14 to 1·97 0·18 None * Low / High 
Maternal SSRI exposure during 
pregnancy 
Jiang, et al. 2018 56502 / 
2858185 
5 Cohort RR 1·37 (1·16 to 1·63) 0·00025 67% 0·79 to 2·39 0·16 Large heterogeneity * Low / High 




2 Cohort HR 1·36 (1·19 to 1·55) 0·000005
9 
0% NA NA Loss of significance under 
10% credibility ceiling * 
High / High 




RR 1·36 (1·25 to 1·47) 7·4E-13 98% 0·88 to 2·08 2·1e-
05 
Large heterogeneity; small 
study effect * 
High / High 




OR 1·3 (1·11 to 1·52) 0·00087 62% 0·84 to 2·01 0·076 Large heterogeneity; small 
study effect; excess 
significance bias 
Low / High 
High frequency cell phone use 
during pregnancy 
Birks, et al. 2017 6922 / 
83884 
5 Cohort OR 1·29 (1·12 to 1·48) 0·00038 0% 1·03 to 1·61 0·52 None NR 
27 
 






OR 1·17 (1·08 to 1·26) 0·0002 78% 0·94 to 1·45 0·3 Large heterogeneity; loss of 
significance under 10% 
credibility ceiling 
High / High 
Breech/transverse presentation Zhu, et al. 2016 29051 / 
1297384 
5 Case-control OR 1·14 (1·06 to 1·22) 0·00039 0% 1·01 to 1·28 1 None Low / High 
Weak (class IV) 
Childhood eating disorder Nazar, et al. 2016 79 / 1072 2 Case-control, 
cross-sectional 
OR 5·64 (3·08 to 
10·33) 
2·2E-08 0% NA NA Loss of significance under 
10% credibility ceiling 
Moderate / 
Moderate 
Preterm birth/low birth weight Franz, et al. 2018 592 / 6163 12 Cohort, case-
control 
OR 3·04 (2·19 to 4·21) 2·7E-11 18% 1·6 to 5·75 0·83 None High / High 






OR 2·1 (1·27 to 3·47) 0·0037 86% 0 to 973·93 0·22 Large heterogeneity High / High 
Childhood/adolescent head trauma Adeyemo, et al. 
2014 
NR / 6255 6 NR RR 2·09 (1·68 to 2·61) 5·5E-11 0% 1·53 to 2·86 0·69 None Critically Low / 
Critically Low 
Gestational diabetes Zhao, et al. 2019 648 / 2516 4 Cohort RR 2 (1·42 to 2·81) 0·000064 0% 0·95 to 4·22 0·038 Small study effect Low / Moderate 




6 Cohort, case 
control, cross-
sectional 
OR 1·91 (1·2 to 3·03) 0·0062 91% 0·37 to 9·79 0·12 Large heterogeneity; excess 
significance bias; loss of 
significance under 10% 
credibility ceiling 
High / High 






OR 1·69 (1·04 to 2·75) 0·035 92% 0·01 to 
462·51 
0·66 Large heterogeneity; loss of 
significance under 10% 
credibility ceiling 
Low / High 






OR 1·59 (1·13 to 2·22) 0·0072 93% 0·46 to 5·44 0·22 Large heterogeneity; loss of 
significance under 10% 








202 / 4137 4 Cohort, case-
control 
RR 1·41 (1·09 to 1·82) 0·0088 0% 0·8 to 2·47 0·49 Loss of significance under 
10% credibility ceiling 
High / High 






OR 1·28 (1·08 to 1·52) 0·0044 0% 1·01 to 1·63 0·068 Loss of significance under 
10% credibility ceiling 
High / High 




30 NR OR 1·2 (1·05 to 1·37) 0·0085 82% 0·7 to 2·07 0·43 Large heterogeneity; loss of 
significance under 10% 
credibility ceiling * 
High / High 





OR 0·7 (0·53 to 0·93) 0·015 74% 0·33 to 1·49 0·014 Large heterogeneity; small 
study effect; loss of 
significance under 10% 
credibility ceiling * 
High / High 
Not significant (NS) 
Maternal hypothyroidism during 
pregnancy 
Thompson, et al. 
2018 
NR / 5317 2 Cohort OR 1·58 (0·5 to 5) 0·44 85% NA NA Large heterogeneity High / High 
Maternal subclinical hypothyroidism 
during pregnancy 
Thompson, et al. 
2018 
NR / 5190 2 Cohort OR 1·34 (0·17 to 
10·47) 
0·78 82% NA NA Large heterogeneity High / High 
Perinatal synthetic oxytocin use Lonfeldt, et al. 
2019 
532 / 1582 3 Cohort, case-
control 
RR 1·17 (0·77 to 1·78) 0·46 86% 0·01 to 
184·42 
0·76 Large heterogeneity Low / High 






OR 1·14 (0·88 to 1·47) 0·33 0% 0·21 to 6·08 0·93 None Low / High 
Prenatal and early infancy thimerosal 
exposure 






OR 1·09 (0·82 to 1·43) 0·56 73% 0·48 to 2·45 0·46 Large heterogeneity Low / High 




Prenatal alcohol exposure <= 20g 
per week 
San Martin 
Porter, et al. 2019 
NR / 
18072 
2 Cohort OR 1·01 (0·68 to 1·5) 0·96 87% NA NA Large heterogeneity Critically Low / Low 
Prenatal alcohol exposure <= 70g 
per week 
San Martin 
Porter, et al. 2019 
NR / 
74502 
7 Cohort OR 0·94 (0·86 to 1·02) 0·14 41% 0·76 to 1·16 0·57 None Critically Low / Low 
Prenatal alcohol exposure <= 50g 
per week 
San Martin 
Porter, et al. 2019 
NR / 
68036 
5 Cohort OR 0·94 (0·85 to 1·04) 0·2 58% 0·69 to 1·28 0·71 Large heterogeneity Critically Low / Low 
All statistical tests are two-tailed. 
*Presence of excess significance bias could not be assessed since necessary data were not reported.  
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; AMSTAR 2, A Measurement Tool to Assess Systematic Reviews 2; CI, confidence interval; HR, hazard ratio; NA, not available; NR, not reported; OR, 




Table 2. Potential peripheral biomarkers of ADHD 
Potential peripheral 
biomarker 
Author, year Number 






















Large heterogeneity, small 
study effect, excess 
significance bias, or loss of 









Highly suggestive (class II) 






WMD -6·93 (-9·34 to -
4·51) 
1·9E-08 94% -14·99 to 1·14 0·47 Large heterogeneity High / High 
Suggestive (class III) 




8 Cross-sectional Hedges' 
g 
-0·55 (-0·82 to -
0·28) 
0·000078 92% -1·43 to 0·34 0·42 Large heterogeneity High / High 
Blood lead He, et al. 2019 1160 / 
2155 
7 Case-control WMD 1 (0·46 to 1·53) 0·00025 97% -0·89 to 2·89 0·36 Large heterogeneity Low / Moderate 
Weak (class IV) 
Serum zinc Sun, et al. 2015 2177 / 
5077 
17 NR Cohen's 
d 
-1·33 (-2·23 to -
0·43) 
0·0038 99% -5·47 to 2·81 0·17 Large heterogeneity Critically Low / 
Low 
Platelet monoamine-oxidase Scassellati, et al. 
2012 
273 / 460 5 Case-control Cohen's 
d 
-1·05 (-1·55 to -
0·55) 
0·000036 67% -2·68 to 0·58 0·32 Large heterogeneity Critically Low / 
Critically Low 
Hair magnesium Huang, et al. 
2019 
155 / 331 4 Cross-sectional Hedges' 
g 
-0·71 (-1·36 to -
0·07) 
0·031 85% -3·63 to 2·2 0·29 Large heterogeneity; loss of 
significance under 10% 
credibility ceiling 





Scassellati, et al. 
2012 
259 / 478 15 Case-control Cohen's 
d 
-0·43 (-0·7 to -
0·15) 
0·0025 53% -1·31 to 0·45 0·87 Large heterogeneity Critically Low / 
Critically Low 
Blood omega-3 Hawkey, et al. 
2014 
311 / 586 9 NR Hedges' 
g 
-0·42 (-0·59 to -
0·26) 
4·5E-07 0% -0·62 to -0·22 0·38 None Critically Low / 
Critically Low 
Saliva cortisol Scassellati, et al. 
2012 
323 / 673 8 Case-control Cohen's 
d 
-0·31 (-0·47 to -
0·15) 
0·00014 0% -0·51 to -0·11 0·79 None Critically Low / 
Critically Low 








-0·25 (-0·44 to -
0·05) 
0·013 83% -1·02 to 0·53 0·43 Large heterogeneity; loss of 
significance under 10% 
credibility ceiling * 
Low / High 




0·31 (0·03 to 0·58) 0·032 52% -0·54 to 1·15 0·0016 Large heterogeneity; small 
study effect; excess 
significance bias; loss of 
significance under 10% 
credibility ceiling 
Low / Moderate 
Urine norepinephrine Scassellati, et al. 
2012 
158 / 249 7 Case-control Cohen's 
d 
0·41 (0·11 to 0·71) 0·0075 16% -0·17 to 0·99 0·71 Excess significance bias; loss 
of significance under 10% 
credibility ceiling 
Critically Low / 
Critically Low 
Urine metanephrine Scassellati, et al. 
2012 
157 / 311 5 Case-control Cohen's 
d 
0·47 (0·1 to 0·84) 0·013 14% -0·32 to 1·27 0·31 Loss of significance under 
10% credibility ceiling 
Critically Low / 
Critically Low 
Urine normetanephrine Scassellati, et al. 
2012 
131 / 222 6 Case-control Cohen's 
d 
0·51 (0·01 to 1·01) 0·047 63% -1·01 to 2·02 0·35 Large heterogeneity; loss of 
significance under 10% 
credibility ceiling 
Critically Low / 
Critically Low 
Not significant (NS) 
Plasma norepinephrine Scassellati, et al. 
2012 
53 / 92 4 Case-control Cohen's 
d 
-0·42 (-1·75 to 
0·91) 




Serum transferrin Tseng, et al. 
2018 
89 / 179 3 Case-control Hedges' 
g 
-0·32 (-0·7 to 0·06) 0·095 36% -3·91 to 3·26 0·59 None Low / High 
Urine homovanillic acid Scassellati, et al. 
2012 
141 / 247 9 Case-control Cohen's 
d 
-0·15 (-0·51 to 0·2) 0·4 43% -1·09 to 0·78 0·25 None Critically Low / 
Critically Low 
Serum iron Tseng, et al. 
2018 




-0·06 (-0·27 to 
0·15) 
0·57 67% -0·67 to 0·55 0·14 Large heterogeneity Low / High 
Urine dopamine Scassellati, et al. 
2012 
99 / 152 4 Case-control Cohen's 
d 
0·13 (-0·22 to 
0·49) 
0·47 4% -0·71 to 0·97 0·078 None Critically Low / 
Critically Low 
Plasma epinephrine Scassellati, et al. 
2012 
53 / 92 4 Case-control Cohen's 
d 
0·19 (-0·59 to 
0·98) 




Scassellati, et al. 
2012 
73 / 122 4 Case-control Cohen's 
d 
0·34 (-0·14 to 
0·81) 
0·16 33% -1·25 to 1·93 0·52 None Critically Low / 
Critically Low 
Urine epinephrine Scassellati, et al. 
2012 
145 / 223 6 Case-control Cohen's 
d 
0·41 (-0·15 to 
0·97) 
0·16 71% -1·39 to 2·2 0·39 Large heterogeneity Critically Low / 
Critically Low 
Peripheral blood brain-
derived neurotrophic factor 
Zhang, et al. 
2018 




0·62 (-0·12 to 
1·35) 
0·099 97% -2·18 to 3·41 0·31 Large heterogeneity Critically Low / 
Low 
All statistical tests are two-tailed. 
*Presence of excess significance bias could not be assessed since necessary data were not reported.  
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; AMSTAR 2, A Measurement Tool to Assess Systematic Reviews 2; CI, confidence interval; NR, not reported; WMD, weighted mean difference 
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